2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate

• ChemBase编号: 1019
• 分子式: C24H25NO4
• 平均质量: 391.4596
• 单一同位素质量: 391.17835829
• SMILES: O(CCN1CCCCC1)C(=O)c1c2oc(c(c(=O)c2ccc1)C)c1ccccc1
• Canonical SMILES: O=C(c1cccc2c1oc(c1ccccc1)c(c2=O)C)OCCN1CCCCC1
• InChI: InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3
• InChIKey: SPIUTQOUKAMGCX-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate
• IUPAC传统名: flavoxate
• 商标名: Urispas
• 别名: Flavoxate HCI; Flavoxate HCL; Flavoxate; 2-(Piperidin-1-yl)ethyl 3-Methyl-4-oxo-2-phenyl-4H-chroMene-8-carboxylate

登记号

• CAS号: 15301-69-6
• PubChem SID: 160964482; 46505138
• PubChem CID: 3354
• CHEBI ID: 5088
• ATC码: G04BD02
• CHEMBL: 1493
• Chemspider ID: 3237
• DrugBank ID: DB01148
• KEGG ID: D07961
• 美国药典/FDA物质标识码: 3E74Y80MEY
• 维基百科标题: Flavoxate
• Medline Plus: a682706

理论计算性质

JChem

• 质子受体: 4
• 质子供体: 0
• LogD (pH = 5.5): 2.4440763
• LogD (pH = 7.4): 3.9847927
• Log P: 4.235423
• 摩尔折射率: 113.5147 cm^3
• 极化性: 43.37562 Å^3
• 极化表面积: 55.84 Å^2
• 可自由旋转的化学键: 6
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 3.65
• LOG S: -4.41
• 溶解度: 1.54e-02 g/l

分子性质

理化性质

• 溶解度: 10 mg/L
• 疏水性(logP): 4.4

产品相关信息

• 纯度: 97%

详细说明

DrugBank - DB01148

• Drug Groups: approved
• Description: A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]
• Indication: For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.
• Pharmacology: Flavoxate is a spasmolytic flavone derivative that acts by relaxing the smooth muscle in the urinary tract. Flavoxate is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Muscarinic receptors play an important role in several major cholin-ergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion.
• Toxicity: The oral LD50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD50 for flavoxate HCl in mice is 1837 mg/kg. Symptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.
• Affected Organisms: Humans and other mammals
• Absorption: Well absorbed from gastrointestinal tract.
• Elimination: 57% of the flavoxate HCl was excreted in the urine within 24 hours.
• External Links: Wikipedia; RxList; PDRhealth; Drugs.com